PRME
NASDAQ
US
Prime Medicine, Inc. - Common Stock
$3.32
▼ $-0.07
(-2.06%)
Vol 1.6M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$626.4M
ROE
-163.5%
Margin
-3301.6%
D/E
0.00
Beta
2.70
52W
$1–$7
Wall Street Consensus
19 analysts · Apr 20266
Strong Buy
8
Buy
5
Hold
0
Sell
0
Strong Sell
73.7%
Buy Rating
Price Chart
Similar Stocks
DSGN
Design Therapeutics Inc
$534.3M
GYRE
Gyre Therapeutics Inc
P/E 96.5
$641.7M
PURR
Hyperliquid Strategies Inc
ALLO
Allogene Therapeutics Inc
$307.9M
OCGN
Ocugen Inc
$421.6M
MDXG
MiMedx Group Inc
P/E 24.6
$1.0B
IRWD
Ironwood Pharmaceuticals Inc
P/E 19.2
$548.2M
PROK
Prokidney Corp
$673.9M
TECX
Tectonic Therapeutic Inc
$390.4M
Earnings
Beat rate: 0.0%
Next Report
May 06, 2026
EPS Estimate: $-0.26
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.26 | — | — |
| Dec 2025 | $-0.26 | $-0.26 | $0.00 |
| Sep 2025 | $-0.26 | $-0.32 | $-0.06 |
| Jun 2025 | $-0.37 | $-0.41 | $-0.04 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -156.2% | -156.2% | -156.2% | -156.2% | -163.5% | -163.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -4716.7% | -4016.8% | -4016.8% | -4016.8% | -3301.6% | -3301.6% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.56 | 3.56 | 3.56 | 3.56 | 6.61 | 6.61 |
Key Ratios
ROA (TTM)
-61.2%
P/S (TTM)
104.80
P/B
2.5
EPS (TTM)
$-1.44
CF/Share
$-1.79
Rev Growth 3Y
-17.0%
52W High
$6.94
52W Low
$1.11
$1.11
52-Week Range
$6.94
How does PRME compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
PRME valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
104.8
▲
716%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
2.5
▲
2%
above
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
PRME profitability vs Biotechnology peers
ROE
-163.5%
▼
143%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-3301.6%
▼
1051%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-61.2%
▼
31%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
PRME financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
6.6
▲
49%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
2.7
▲
179%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
PRME fundamentals radar
PRME
Peer median
Industry
PRME profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
PRME vs peers: key metrics
Latest News
No related news yet